<DOC>
	<DOCNO>NCT00729118</DOCNO>
	<brief_summary>RATIONALE : Vorinostat may stop growth cancer cell block enzymes need cell growth . Lenalidomide may stop growth multiple myeloma block blood flow cancer . Giving vorinostat together lenalidomide may kill cancer cell . PURPOSE : This phase I trial study side effect best dose vorinostat give together lenalidomide autologous stem cell transplant treat patient multiple myeloma .</brief_summary>
	<brief_title>Vorinostat Lenalidomide After Autologous Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess dose-limiting toxicity safety vorinostat lenalidomide autologous peripheral blood stem cell transplantation patient multiple myeloma . - To evaluate overall response rate combination Vorinostat ( SAHA ) lenalidomide . Secondary - To evaluate effect treatment regimen natural killer cell activity regulatory T cell post-transplant period . - To determine preliminary clinical activity treatment regimen assess overall survival progression-free survival patient . - To obtain pilot data regard association treatment regimen patient quality life circulate inflammatory cytokine . OUTLINE : This dose-escalation study vorinostat . Patients receive oral vorinostat alone daily day 1-21 course 1 . For second subsequent course , patient receive oral vorinostat combination oral lenalidomide daily day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo blood sample collection periodically correlative laboratory study . Studies include functional immune assay ( T-cell natural killer cell activity regulatory T-cell recovery ) fluorescence activate cell sort ( FACS ) ELISPOT ; analysis inflammatory marker ( cytokine catecholamine ) ; analysis global H3 H4 acetylation immunohistochemistry . Quality life assess periodically use Brief Pain Inventory ( Short Form ) , The Center Epidemiologic Studies Depression Scale ( CES-D-10 ) , 9-item Brief Fatigue Inventory , FACT-G questionnaire . After completion study treatment , patient follow least 30 day .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Has undergone melphalanconditioned autologous peripheral blood stem cell transplant myeloma . PATIENT CHARACTERISTICS : ECOG/WHO performance status 02 ANC ≥ 1,000/mm³ Platelet count ≥ 75,000/mm³ Total bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 2 time ULN Serum creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 90 day completion study treatment No blood , sperm , ova donation ≥ 4 week completion study treatment Able obtain commercially available lenalidomide via Celegene 's RevAssist® program Registered RevAssist® program Willing able comply requirement RevAssist® Able swallow capsule No severe uncontrolled systemic illness No `` currently active '' second malignancy , nonmelanoma skin cancer carcinoma situ cervix Patients consider `` currently active '' malignancy complete therapy malignancy , disease free malignancy &gt; 5 year , consider physician &lt; 30 % risk relapse No congenital long QT syndrome No drug alcohol abuse within past 12 month No history allergic reaction ( include erythema nodosum ) attribute compound similar chemical biologic composition lenalidomide , thalidomide , vorinostat No medical condition , include mental illness substance abuse , deem investigator ( ) likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation study result PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior class Ia , Ib , Ic antiarrhythmic medication No prior HDAC inhibitorlike compound ( e.g. , valproic acid ) anticancer therapy More 30 day since prior HDAC inhibitorlike compound indication ( e.g. , valproic acid epilepsy ) No prior gastrointestinal surgery procedure may , opinion investigator , interfere absorption swallow study drug No concurrent corticosteroids physiologic maintenance treatment No concurrent radiotherapy , unless local control bone pain Irradiated area small possible Lesions within irradiated field use response assessment No concurrent use complementary alternative medicine would confound interpretation toxicity anticancer activity study drug No concurrent anticancer therapy , include chemotherapy biologic therapy No concurrent HDAC inhibitor ( e.g. , valproic acid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>